Concepedia

Ujjwala Vijapurkar

UV

Statistics

Publications

35

Citations

3.9K

H-Index

23

Active since

1996

Affiliations

Janssen (United States)(Current)

Janssen Scientific Affairs (United States)

Johnson & Johnson (United States)

Cleveland Clinic

Memorial Sloan Kettering Cancer Center

Ujjwala Vijapurkar is an author at Janssen (United States) specializing in pharmacotherapy, pharmacology, and medicine.

Publications per year

1996–2021

35

Publications

35

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Alok A. Khorana, Gerald A. Soff, Ajay K. Kakkar et al. · New England Journal of Medicine · 2019 · 714 citations · Full text

, , +17

Topiramate in migraine prophylaxis

Hans‐Christoph Diener, P Tfelt-Hansen, C. Dahl�f et al. · Journal of Neurology · 2004 · 343 citations

, , +13

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

W. Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter et al. · Metabolism · 2018 · 268 citations · Full text

, , +17

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

David Hough, Srihari Gopal, Ujjwala Vijapurkar et al. · Schizophrenia Research · 2009 · 267 citations

, , +13

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Thomas Först, Robert Guthrie, Ronald Goldenberg et al. · Diabetes Obesity and Metabolism · 2014 · 253 citations · Full text

, , +13

1–5 of 35